pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

138 catalysts · 4,876 phase readout · 2,367 8k filing · 286 earnings · 275 pdufa · 138 phase 2 completion · 64 phase 1 completion

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-07-20: 0 catalysts2026-07-21: 0 catalysts2026-07-22: 0 catalysts2026-07-23: 0 catalysts2026-07-24: 0 catalysts2026-07-25: 0 catalysts2026-07-26: 0 catalysts2026-07-27: 2 catalysts2026-07-28: 4 catalysts2026-07-29: 12 catalysts2026-07-30: 12 catalysts2026-07-31: 3 catalysts2026-08-01: 0 catalysts2026-08-02: 0 catalysts2026-08-03: 4 catalysts2026-08-04: 12 catalysts2026-08-05: 14 catalysts2026-08-06: 10 catalysts2026-08-07: 1 catalyst2026-08-08: 0 catalysts2026-08-09: 0 catalysts2026-08-10: 1 catalyst2026-08-11: 1 catalyst2026-08-12: 1 catalyst2026-08-13: 0 catalysts2026-08-14: 0 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 0 catalysts2026-08-18: 1 catalyst2026-08-19: 0 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 0 catalysts2026-08-27: 0 catalysts2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 0 catalysts2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 0 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 0 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 0 catalysts2026-10-14: 0 catalysts2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts
view
agendamonth
show past →
sort
soonestlatesttypesponsoralpha
type: phase 2 completion×clear all
type
  • phase readout4,876
  • 8k filing2,367
  • earnings286
  • pdufa275
  • phase 2 completion138
  • phase 1 completion64
phase 1 initiation
39
  • phase 2 initiation35
  • phase 1 2 completion29
  • phase 0 trial completion22
  • therapy area
    • Oncology29
    • Cardiology10
    • Women's Health8
    • Immunology8
    • Infectious Disease6
    • Pulmonology5
    • Dermatology5
    • Ophthalmology3
    • Pain3

    Week of Apr 27, 2026

    50
    ›Apr 27, 2026phase 2 completion91d agoSustained Therapeutics Inc — lidocaine SR (Phase II Trial Completion)LIDOCAINE

    Therapy area: Central Nervous System. Indication: Post-Operative Pain

    full page →LIDOCAINE →source: globaldata
    ›Apr 27, 2026phase 2 completion91d agoSMBT Ayurved College and Hospital — ayurvedic medicine (Phase II Trial Completion)ayurvedic medicine

    Therapy area: Ophthalmology. Indication: Keratoconjunctivitis Sicca (Dry Eye)

    full page →ayurvedic medicine →source: globaldata
    ›Apr 27, 2026phase 2 completion91d agoChacha Nehru Bal Chikitsalaya — bupivacaine (Phase II Trial Completion)bupivacaine

    Therapy area: Central Nervous System. Indication: Post-Operative Pain

    full page →bupivacaine →source: globaldata
    ›Apr 27, 2026phase 2 completion91d agoEuropean and Developing Countries Clinical Trials Partnership — (diphtheria + tetanus + pertussis (whole cell) + hepatitis B + haemophilus influenzae [serotype B]) vaccine (Phase II Trial Completion)(diphtheria + tetanus + pertussis (whole cell) + hepatitis B + haemophilus influenzae [serotype B]) vaccine

    Therapy area: Infectious Disease. Indication: Salmonella Infections

    full page →(diphtheria + tetanus + pertussis (whole cell) + hepatitis B + haemophilus influenzae [serotype B]) vaccine →source: globaldata
    ›Apr 27, 2026phase 2 completion91d agoOrthomedico Inc — lactococcus lactis subsp. cremoris YRC3780 (Phase II Trial Completion)lactococcus lactis subsp. cremoris YRC3780

    Therapy area: Central Nervous System. Indication: Sleep Disorders

    full page →lactococcus lactis subsp. cremoris YRC3780 →source: globaldata
    ›Apr 27, 2026phase 2 completion91d agoPt.Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences Rohtak — nivolumab (Phase II Trial Completion)nivolumab

    Therapy area: Oncology. Indication: Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Squamous Non-Small Cell Lung Cancer

    full page →nivolumab →source: globaldata
    ›Apr 27, 2026phase 2 completion91d agoChina Red Cross Foundation — sufentanil (Phase II Trial Completion)sufentanil

    Therapy area: Gastrointestinal, Genito Urinary System. Indication: Hernia, Urinary Retention

    full page →sufentanil →source: globaldata
    ›Apr 27, 2026phase 2 completion91d agoKonya City Hospital — fentanyl (Phase II Trial Completion)fentanyl ER

    Therapy area: Central Nervous System, Gastrointestinal. Indication: Post-Operative Pain, Postoperative Ileus

    full page →fentanyl ER →source: globaldata
    ›Apr 27, 2026phase 2 completion91d agoBC Children's Hospital Research Institute — dexamethasone (Phase II Trial Completion)dexamethasone

    Therapy area: Central Nervous System, Gastrointestinal. Indication: Appendicitis, Post-Operative Pain

    full page →dexamethasone →source: globaldata
    ›Apr 28, 2026phase 2 completion90d agoChangzhou Hengbang Pharmaceutical Co Ltd — HS-10374 (Phase II Trial Completion)HS-10374

    Therapy area: Musculoskeletal Disorders. Indication: Psoriatic Arthritis

    full page →HS-10374 →source: globaldata
    ›Apr 28, 2026phase 2 completion90d agoKS Hegde Medical Academy — fentanyl (Phase II Trial Completion)fentanyl ER

    Therapy area: Hormonal Disorders. Indication: Endocrine Gland Disorders

    full page →fentanyl ER →source: globaldata
    ›Apr 28, 2026phase 2 completion90d agoInonu University — albumin gel- and platelet- rich fibrin (Phase II Trial Completion)albumin gel- and platelet- rich fibrin

    Therapy area: Immunology, Mouth and Dental Disorders. Indication: Inflammation, Periodontal Disease, Periodontitis

    full page →albumin gel- and platelet- rich fibrin →source: globaldata
    ›Apr 28, 2026phase 2 completion90d agoUmraniye Research Hospital — bupivacaine (Phase II Trial Completion)bupivacaine

    Therapy area: Central Nervous System. Indication: Post-Operative Pain

    full page →bupivacaine →source: globaldata
    ›Apr 28, 2026phase 2 completion90d agoAnanta Institute of Medical Sciences and Research Centre — levobupivacaine (Phase II Trial Completion)levobupivacaine

    Therapy area: Central Nervous System, Gastrointestinal. Indication: Inguinal Hernia, Post-Operative Pain

    full page →levobupivacaine →source: globaldata
    ›Apr 28, 2026phase 2 completion90d agoGastroenterological Association of Thailand — metadoxine (Phase II Trial Completion)metadoxine

    Therapy area: Gastrointestinal. Indication: Metabolic and Alcohol-Associated Liver Disease (MetALD), Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD or NAFLD)

    full page →metadoxine →source: globaldata
    ›Apr 28, 2026phase 2 completion90d agoTianjin Medical University Cancer Institute and Hospital — AG [gemcitabine + nab-paclitaxel] (Phase II Trial Completion)AG [gemcitabine + nab-paclitaxel]

    Therapy area: Oncology. Indication: Pancreatic Cancer

    full page →AG [gemcitabine + nab-paclitaxel] →source: globaldata
    ›Apr 28, 2026phase 2 completion90d agoHackensack Meridian Health Inc — carboplatin (Phase II Trial Completion)Carboplatin Pfizer

    Therapy area: Oncology. Indication: Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma

    full page →Carboplatin Pfizer →source: globaldata
    ›Apr 28, 2026phase 2 completion90d agoTamilnadu Government Dental College and Hospital — metformin (Phase II Trial Completion)metformin

    Therapy area: Mouth and Dental Disorders. Indication: Unspecified Mouth and Dental Disorders

    full page →metformin →source: globaldata
    ›Apr 28, 2026phase 2 completion90d agoArdabil University of Medical Sciences — chorionic gonadotropin (Phase II Trial Completion)chorionic gonadotropin

    Therapy area: Women's Health. Indication: Female Infertility

    full page →chorionic gonadotropin →source: globaldata
    ›Apr 28, 2026phase 2 completion90d agoShanghai Pulmonary Hospital — undisclosed programmed cell death protein 1 inhibitor (Phase II Trial Completion)undisclosed programmed cell death protein 1 inhibitor

    Therapy area: Oncology. Indication: Non-Small Cell Lung Cancer

    full page →undisclosed programmed cell death protein 1 inhibitor →source: globaldata
    ›Apr 28, 2026phase 2 completion90d agoAl-Mustansiriya University — platelet rich fibrin (Phase II Trial Completion)platelet rich fibrin

    Therapy area: Mouth and Dental Disorders. Indication: Periodontitis

    full page →platelet rich fibrin →source: globaldata
    ›Apr 28, 2026phase 2 completion90d agoWest China Hospital of Stomatology — dexamethasone (Phase II Trial Completion)dexamethasone

    Therapy area: Mouth and Dental Disorders. Indication: Aphthous Ulcers (Canker Sores)

    full page →dexamethasone →source: globaldata
    ›Apr 28, 2026phase 2 completion90d agoUniversity of Sao Paulo General Hospital — iloprost (Phase II Trial Completion)iloprost

    Therapy area: Cardiovascular. Indication: Pulmonary Arterial Hypertension

    full page →iloprost →source: globaldata
    ›Apr 29, 2026phase 2 completion89d agoCARsgen Therapeutics Holdings Ltd — CT-0594CP CAR-T Cells (Phase II Trial Completion)CT-0594CP CAR-T Cells

    Therapy area: Oncology. Indication: Multiple Myeloma (Kahler Disease), Plasma Cell Neoplasm, Refractory Multiple Myeloma, Relapsed Multiple Myeloma

    full page →CT-0594CP CAR-T Cells →source: globaldata
    ›Apr 29, 2026phase 2 completion89d agoTexas Christian University — Alii Supplement (Phase II Trial Completion)Alii Supplement

    Therapy area: Nutritional Disorders. Indication: Unspecified Nutritional Disorders

    full page →Alii Supplement →source: globaldata
    ›Apr 29, 2026phase 2 completion89d agoMassachusetts Eye and Ear Infirmary — N-acetylcysteine (Phase II Trial Completion)N-acetylcysteine

    Therapy area: Ophthalmology. Indication: Cataract, Fuchs Endothelial Corneal Dystrophy (FECD)

    full page →N-acetylcysteine →source: globaldata
    ›Apr 29, 2026phase 2 completion89d agoNational Heart Lung and Blood Institute — danazol (Phase II Trial Completion)danazol

    Therapy area: Gastrointestinal, Genetic Disorders, Hematological Disorders, Respiratory. Indication: Cytopenia, Liver Fibrosis, Mutational Disorders, Pulmonary Fibrosis

    full page →danazol →source: globaldata
    ›Apr 29, 2026phase 2 completion89d agoSaraswati Dhanwantari Dental College and Hospital Parbhani — (amoxicillin + clavulanic acid) (Phase II Trial Completion)(amoxicillin + clavulanic acid)

    Therapy area: Infectious Disease, Mouth and Dental Disorders. Indication: Periodontitis, Unspecified Infectious Diseases

    full page →(amoxicillin + clavulanic acid) →source: globaldata
    ›Apr 29, 2026phase 2 completion89d agoBangalore Medical College and Research Institute — dinoprostone (Phase II Trial Completion)dinoprostone ER

    Therapy area: Dermatology. Indication: Vitiligo

    full page →dinoprostone ER →source: globaldata
    ›Apr 29, 2026phase 2 completion89d agoNational Institute of Unani Medicine — unani medicine (Phase II Trial Completion)unani medicine

    Therapy area: Women's Health. Indication: Menorrhagia

    full page →unani medicine →source: globaldata
    ›Apr 30, 2026phase 2 completion88d agoUsynova Pharmaceuticals Ltd — UA-021 (Phase II Trial Completion)UA-021

    Therapy area: Immunology. Indication: Plaque Psoriasis (Psoriasis Vulgaris), Psoriasis

    full page →UA-021 →source: globaldata
    ›Apr 30, 2026phase 2 completion88d agoCairo University — lidocaine (Phase II Trial Completion)LIDOCAINE

    Therapy area: Central Nervous System. Indication: Post-Operative Pain

    full page →LIDOCAINE →source: globaldata
    ›Apr 30, 2026phase 2 completion88d agoVeer Chandra Singh Garhwali Government Medical Science and Research Institute — bupivacaine (Phase II Trial Completion)bupivacaine

    Therapy area: Ear Nose Throat Disorders. Indication: Otitis Media

    full page →bupivacaine →source: globaldata
    ›Apr 30, 2026phase 2 completion88d agoUniversity of Benin Teaching Hospital — doxycycline (Phase II Trial Completion)doxycycline ER

    Therapy area: Women's Health. Indication: Unspecified Gynecological Disorders

    full page →doxycycline ER →source: globaldata
    ›Apr 30, 2026phase 2 completion88d agoVaidya Yagya Dutt Sharma Ayurvedic P. G. Mahavidhyalaya — ayurvedic medicine (Phase II Trial Completion)ayurvedic medicine

    Therapy area: Dermatology. Indication: Burns

    full page →ayurvedic medicine →source: globaldata
    ›Apr 30, 2026phase 2 completion88d agoGandhi Medical College & Hospital — dexmedetomidine (Phase II Trial Completion)dexmedetomidine

    Therapy area: Oncology. Indication: Malignant Neoplasms

    full page →dexmedetomidine →source: globaldata
    ›Apr 30, 2026phase 2 completion88d agoZhejiang Provincial People's Hospital — telitacicept (Phase II Trial Completion)telitacicept

    Therapy area: Immunology. Indication: Rheumatoid Arthritis

    full page →telitacicept →source: globaldata
    ›Apr 30, 2026phase 2 completion88d agoDalian Municipal Central Hospital — dexamethasone (Phase II Trial Completion)dexamethasone

    Therapy area: Central Nervous System. Indication: Post-Operative Pain

    full page →dexamethasone →source: globaldata
    ›Apr 30, 2026phase 2 completion88d agoSmt.B.K.Shah Medical Institute & Research Centre & Dhiraj Hospital — dexmedetomidine (Phase II Trial Completion)dexmedetomidine

    Therapy area: Central Nervous System. Indication: Sedation

    full page →dexmedetomidine →source: globaldata
    ›Apr 30, 2026phase 2 completion88d agoKSO Corp — undisclosed plant extract (Phase II Trial Completion)undisclosed plant extract

    Therapy area: Genito Urinary System. Indication: Unspecified Genito Urinary Disorders

    full page →undisclosed plant extract →source: globaldata
    ›Apr 30, 2026phase 2 completion88d agoThe First Affiliated Hospital of Guangxi Medical University — fospropofol disodium (Phase II Trial Completion)fospropofol disodium

    Therapy area: Central Nervous System. Indication: Sedation

    full page →fospropofol disodium →source: globaldata
    ›Apr 30, 2026phase 2 completion88d agoQinghai Provincial Xining Third People's Hospital — amoxicillin (Phase II Trial Completion)amoxicillin

    Therapy area: Gastrointestinal, Infectious Disease. Indication: Gastritis, Helicobacter pylori Infections

    full page →amoxicillin →source: globaldata
    ›Apr 30, 2026phase 2 completion88d agoQilu Pharmaceutical Co Ltd — iruplinalkib (Phase II Trial Completion)iruplinalkib

    Therapy area: Oncology. Indication: Non-Small Cell Lung Cancer

    full page →iruplinalkib →source: globaldata
    ›Apr 30, 2026phase 2 completion88d agoTufts Medical Center — phytonadione (Phase II Trial Completion)PHYTONADIONE

    Therapy area: Musculoskeletal Disorders. Indication: Osteoarthritis

    full page →PHYTONADIONE →source: globaldata
    ›Apr 30, 2026phase 2 completion88d agoDanone Research & Innovation — (prebiotics + probiotic + protein blend + micronutrient blend) (Phase II Trial Completion)(prebiotics + probiotic + protein blend + micronutrient blend)

    Therapy area: Central Nervous System, Metabolic Disorders. Indication: Ageing, Unspecified Psychiatric Disorders

    full page →(prebiotics + probiotic + protein blend + micronutrient blend) →source: globaldata
    ›Apr 30, 2026phase 2 completion88d agoNational Health and Medical Research Council — docosahexaenoic acid (Phase II Trial Completion)docosahexaenoic acid

    Therapy area: Women's Health. Indication: Labor And Delivery

    full page →docosahexaenoic acid →source: globaldata
    ›Apr 30, 2026phase 2 completion88d agoChildren’s Hospital of Chongqing Medical University — iKids-Growth (Phase II Trial Completion)iKids-Growth

    Therapy area: Hormonal Disorders. Indication: Shox Deficiency

    full page →iKids-Growth →source: globaldata
    ›Apr 30, 2026phase 2 completion88d agoRegeneron Pharmaceuticals Inc — cemiplimab (Phase II Trial Completion)cemiplimab

    Therapy area: Oncology. Indication: Adenocarcinoma, Colon Cancer, Colorectal Cancer

    full page →cemiplimab →source: globaldata
    ›Apr 30, 2026phase 2 completion88d agoIntas Pharmaceuticals Ltd — olaparib (Phase II Trial Completion)olaparib

    Therapy area: Oncology. Indication: Breast Cancer, Castration-Resistant Prostate Cancer (CRPC), Epithelial Ovarian Cancer, Fallopian Tube Cancer, Metastatic Breast Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Peritoneal Cancer, Solid Tumor

    full page →olaparib →source: globaldata
    ›Apr 30, 2026phase 2 completion88d agoGuy's and St Thomas' NHS Foundation Trust — autologous regulatory T cells (Phase II Trial Completion)autologous regulatory T cells

    Therapy area: Genito Urinary System, Immunology. Indication: End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), Kidney Transplant Rejection

    full page →autologous regulatory T cells →source: globaldata
    ← prev
    page 1 of 3
    next →
    $REGN656.01+0.63%